12040 115th Ave., NE
Kirkland, WA 98034
Office: (425) 823-0400
Fax: (425) 823-8508
ProteoTech Inc., is a private drug development Company founded in 1996 that is located in the Seattle, WA area (Kirkland, WA), and is focused on targeting misfolded proteins and amyloid diseases. ProteoTech is utilizing its amyloid and proteoglycan expertise in an effort to transform the lives of victims of Alzheimer's disease, Parkinson's disease, type 2 diabetes and systemic amyloid disease (including AL, TTR and AA amyloidosis).
With over 225 patents in its intellectual property estate, ProteoTech is in human clinical trials for its orally active small molecule drug Exebryl-1® for the treatment of mild-to-moderate Alzheimer's disease, and an orally active small molecule drug, Systebryl™, for the treatment of AL (immunoglobulin light chain) amyloidosis.
The Company is in late stage pre-clinical development with Synuclere™ for the treatment of Parkinson's disease, and is also in late stage pre-clinical development for a novel small peptide called PeptiClere™ for the treatment of Alzheimer's disease. ProteoTech is additionally developing a novel small molecule compound for the treatment of amyloidosis associated with type 2 diabetes.